Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study
- 1 July 2003
- journal article
- Published by Elsevier in Schizophrenia Research
- Vol. 62 (1-2) , 77-88
- https://doi.org/10.1016/s0920-9964(02)00431-0
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Bodyweight Gain with Atypical AntipsychoticsDrug Safety, 2001
- A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatmentInternational Clinical Psychopharmacology, 2000
- A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophreniaPsychological Medicine, 2000
- Do Phase III Trials Have Clinical Value?Journal of Clinical Psychopharmacology, 1999
- Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trialsJournal of Psychopharmacology, 1997
- ICI 204,636, an Atypical AntipsychoticJournal of Clinical Psychopharmacology, 1996
- Weight and mortality in finnish womenJournal of Clinical Epidemiology, 1991
- Weight, Diet, and the Risk of Symptomatic Gallstones in Middle-Aged WomenNew England Journal of Medicine, 1989
- The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patientsActa Psychiatrica Scandinavica, 1987
- Induction of Obesity by Psychotropic DrugsAnnals of the New York Academy of Sciences, 1987